NO20022333L - New use of antibodies as vaccines - Google Patents

New use of antibodies as vaccines

Info

Publication number
NO20022333L
NO20022333L NO20022333A NO20022333A NO20022333L NO 20022333 L NO20022333 L NO 20022333L NO 20022333 A NO20022333 A NO 20022333A NO 20022333 A NO20022333 A NO 20022333A NO 20022333 L NO20022333 L NO 20022333L
Authority
NO
Norway
Prior art keywords
vaccines
antibodies
new use
new
Prior art date
Application number
NO20022333A
Other languages
Norwegian (no)
Other versions
NO20022333D0 (en
Inventor
Hans Loibner
Helmut Eckert
Gottfried Himmler
Original Assignee
Igeneon Krebs Immuntherapie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igeneon Krebs Immuntherapie filed Critical Igeneon Krebs Immuntherapie
Publication of NO20022333D0 publication Critical patent/NO20022333D0/en
Publication of NO20022333L publication Critical patent/NO20022333L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20022333A 1999-11-16 2002-05-15 New use of antibodies as vaccines NO20022333L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0192799A AT409086B (en) 1999-11-16 1999-11-16 NEW USE OF ANTIBODIES AS VACCINE
PCT/EP2000/011306 WO2001035989A2 (en) 1999-11-16 2000-11-15 Use of anti-idiotypical antibodies as vaccines against cancer

Publications (2)

Publication Number Publication Date
NO20022333D0 NO20022333D0 (en) 2002-05-15
NO20022333L true NO20022333L (en) 2002-06-03

Family

ID=3524036

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022333A NO20022333L (en) 1999-11-16 2002-05-15 New use of antibodies as vaccines

Country Status (24)

Country Link
EP (1) EP1229936B1 (en)
JP (1) JP2003514028A (en)
KR (1) KR20020060968A (en)
CN (1) CN1390138A (en)
AT (1) AT409086B (en)
AU (1) AU780853B2 (en)
BR (1) BR0015597A (en)
CA (1) CA2391927A1 (en)
CZ (1) CZ20021707A3 (en)
DE (1) DE50006526D1 (en)
DK (1) DK1229936T3 (en)
EE (1) EE200200252A (en)
ES (1) ES2218272T3 (en)
HU (1) HUP0204216A2 (en)
IL (1) IL149614A0 (en)
IS (1) IS6381A (en)
MX (1) MXPA02004942A (en)
NO (1) NO20022333L (en)
NZ (1) NZ518669A (en)
PL (1) PL356770A1 (en)
PT (1) PT1229936E (en)
SK (1) SK6542002A3 (en)
TR (1) TR200401267T4 (en)
WO (1) WO2001035989A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017108A (en) * 1975-04-17 1977-04-12 Archibald Kenrick And Sons Limited Window stay
US6294171B2 (en) * 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
AT410172B (en) * 2000-03-21 2003-02-25 Igeneon Gmbh METHOD FOR PRODUCING VACCINE FORMULATION
AT410637B (en) * 2001-06-01 2003-06-25 Igeneon Krebs Immuntherapie USE OF POLYCLONAL IMMUNOGLOBULINES
AT502293B1 (en) * 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie IMMUNOGENERAL, MONOCLONAL ANTIBODY
AT500648B1 (en) * 2002-08-12 2010-03-15 Igeneon Krebs Immuntherapie SET FOR THE TREATMENT OF CANCER PATIENTS
KR100522526B1 (en) * 2002-11-28 2005-10-19 주식회사 바이넥스 Method of Preparing Dendritic cell for Immunotherapy
AT500650B1 (en) 2003-04-17 2009-11-15 Altropus Gmbh IMMUNOGENIC RECOMBINANT ANTIBODY
WO2007024825A2 (en) * 2005-08-26 2007-03-01 Genway Biotech, Inc. Immunoaffinity separation and analysis compositions and methods
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
US20180008702A1 (en) * 2014-12-05 2018-01-11 Celltrion Inc. Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002848A1 (en) * 1983-01-28 1984-08-02 Centocor Inc Anti-idiotypic antibodies to t cell antigen receptors
NZ229159A (en) * 1988-05-17 1992-11-25 Soldano Ferrone Anti-idiotype antibodies which bind to the idiotype of murine antibody 225.28
US20030072751A1 (en) * 1990-03-14 2003-04-17 Heribert Bohlen Idiotypic vaccination against b cell lymphoma
IT1254315B (en) * 1992-03-27 1995-09-14 Mini Ricerca Scient Tecnolog ANTI-IDIOTYPIC MONOCLONAL ANTIBODIES DIRECT AGAINST ANTI-TNF ANTIBODIES.
CA2139756A1 (en) * 1992-07-08 1994-01-20 Eric M. Bonnem Use of gm-csf as a vaccine adjuvant
AU704829B2 (en) * 1994-12-28 1999-05-06 University Of Kentucky Murine anti-idiotype antibody 3H1

Also Published As

Publication number Publication date
EP1229936A2 (en) 2002-08-14
CZ20021707A3 (en) 2002-10-16
TR200401267T4 (en) 2004-07-21
MXPA02004942A (en) 2003-10-14
EP1229936B1 (en) 2004-05-19
CN1390138A (en) 2003-01-08
AU2357201A (en) 2001-05-30
DK1229936T3 (en) 2004-08-30
PL356770A1 (en) 2004-07-12
NO20022333D0 (en) 2002-05-15
ATA192799A (en) 2001-10-15
CA2391927A1 (en) 2001-05-25
SK6542002A3 (en) 2002-11-06
ES2218272T3 (en) 2004-11-16
NZ518669A (en) 2003-08-29
IL149614A0 (en) 2002-11-10
EE200200252A (en) 2003-06-16
PT1229936E (en) 2004-09-30
HUP0204216A2 (en) 2003-04-28
KR20020060968A (en) 2002-07-19
IS6381A (en) 2002-05-14
BR0015597A (en) 2002-07-23
AU780853B2 (en) 2005-04-21
WO2001035989A2 (en) 2001-05-25
WO2001035989A3 (en) 2001-10-04
DE50006526D1 (en) 2004-06-24
JP2003514028A (en) 2003-04-15
AT409086B (en) 2002-05-27

Similar Documents

Publication Publication Date Title
SE0001090D0 (en) Oxime derivatives and their use as latent acids
DK1210113T3 (en) Combined vaccine preparations
NO20014325L (en) Vaccine
CY2007029I1 (en) METHOD FOR THE PREPARATION OF SUBSTITUTED OCTANOYL-AMIDES
DE60045324D1 (en) vaccine composition
CY2011008I1 (en) FLU VACCINE
DE60217126D1 (en) PREPARATION OF AMINO-PRIMIDINE COMPOUNDS
NO20015855D0 (en) New use of compounds as antibacterial agents
ID30393A (en) TIENOPIRIMIDINA COMPOUNDS, MAKING AND USE OF IT
DE60002650D1 (en) Oil-vaccinated vaccine
NO20020763L (en) Vaccine
NO20044916L (en) Preparations of sulfinylacetamide
DE60019960D1 (en) PREPARATION OF ISOBUTENCOPOLYMERS
NO20022333L (en) New use of antibodies as vaccines
NO20042667L (en) Procedure for the preparation of escitalopram
DK1216250T3 (en) Thienoisoxazolyl and thienylpyrazolyl-phenoxy-substituted propyl derivatives as D4 antagonists
NO20041968L (en) Use of cystationin
NO20025423D0 (en) Procedure for the preparation of Citalopram
NO20021730D0 (en) New formulation of mirtazapine
DE60016608D1 (en) PREPARATION OF SULPHONYLIMINE COMPOUNDS
NO20030515D0 (en) Process for the preparation of dinapsoline
NO20004816D0 (en) New pharmaceutical formulation
NO20014845D0 (en) Use of arylalkanoylpyridazines
NO20023702L (en) Process for the preparation of 5-arylnicotinaldehydes
NO20021249L (en) Tienoisoxazolphenoxy substituted ethyl and propyl derivatives useful as D4 antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application